Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01979406 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
A Phase 1 study, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT01979406 is a Phase 1 study that has completed, run by Emergent BioSolutions. The registered enrollment target is 120 participants.
The verdict
NCT01979406, a Phase 1 study, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate 2 vaccine candidates against anthrax compared to the positive (vaccine) control as studied in normal healthy volunteers.
Interventions
- BIOLOGICAL AVA
- BIOLOGICAL Ad4-PA-1
- BIOLOGICAL Ad4-PA-GPI-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01979406
The ClinicalTrials.gov registry entry for NCT01979406 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AVA is the first listed.
NCT01979406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01979406 about?
NCT01979406 is a clinical study titled "A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines". The purpose of this study is to evaluate 2 vaccine candidates against anthrax compared to the positive (vaccine) control as studied in normal healthy volunteers.
What is the current status of trial NCT01979406?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2013-11. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01979406?
The interventions under investigation include: AVA (BIOLOGICAL), Ad4-PA-1 (BIOLOGICAL), Ad4-PA-GPI-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01979406?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.